Biomarin Pharmaceutical (BMRN) Capital Expenditures (2009 - 2026)

Biomarin Pharmaceutical has disclosed Capital Expenditures across 18 years of filings, most recently posting $20.9 million for Q1 2026.

• Quarterly Capital Expenditures rose 24.78% year-over-year to $20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.2 million (up 40.88% YoY) and the FY2025 annual result came in at $103.0 million, up 20.62% from the prior year.
• Capital Expenditures retreated to $20.9 million in Q1 2026, from $40.7 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $40.7 million in Q4 2025 and troughed at $16.8 million in Q1 2025.
• A 5-year average of $25.1 million and a median of $24.5 million in 2023 frame the typical range for Capital Expenditures.
• Biggest YoY gain for Capital Expenditures was 108.51% in 2025; the steepest drop was 35.76% in 2025.
• Tracing BMRN's Capital Expenditures over 5 years: stood at $35.7 million in 2022, then fell by 18.97% to $28.9 million in 2023, then slumped by 32.46% to $19.5 million in 2024, then jumped by 108.51% to $40.7 million in 2025, then slumped by 48.62% to $20.9 million in 2026.
• Business Quant data shows BMRN's Capital Expenditures at $20.9 million in Q1 2026, $40.7 million in Q4 2025, and $28.4 million in Q3 2025.